Investor List:

Top Therapeutics Series A Investors in New York City (18)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top Therapeutics investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Josh Wolfe, Managing Partner at Lux Capital
Josh Wolfe
Lux Capital·Managing Partner
Sweet spot: $10.0M
Range: $1M - $50.0M
Investors in New York (NY), Investors in Menlo Park (CA)
Photo of Geoffrey Smith, Managing Partner at Digitalis Ventures
Geoffrey Smith
Digitalis Ventures·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY), Investors in Los Angeles (CA), Investors in San Francisco (CA), Investors in Boston (MA)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Manufacturing (Series B), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in Manufacturing (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Los Angeles / Southern California (Other Lists), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Seed), Investors in San Francisco Bay Area (Other Lists), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Seed), Investors in Manufacturing (Seed), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Manufacturing (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in Manufacturing (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health IT (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Manufacturing (Series B), Investors in Boston / New England (Other Lists), Investors in Diagnostics (Series A), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Series A), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Diagnostics (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Pablo Lubroth, Investor at Hummingbird Ventures
Pablo Lubroth
Sweet spot: $2.8M
Range: $500K - $5.0M
Investors in London, Investors in New York (NY)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in London (Other Lists), Investors in Digital Health (Series B), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in DeepTech (Seed), Investors in DeepTech (Series A), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in DeepTech (Series B), Investors in DeepTech (Series A), Investors in DeepTech (Seed), Investors in Pharmaceuticals (Pre-seed), Investors in DeepTech (Series B), Investors in DeepTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Pharmaceuticals (Pre-seed), Investors in Therapeutics (Series A), Investors in Digital Health (Pre-seed), Investors in BioTech (Pre-seed), Investors in Digital Health (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Pre-seed), Investors in DeepTech (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series B), Investors in BioTech (Pre-seed), Investors in Digital Health (Series A), Investors in Digital Health (Seed)
Photo of Todd Pietri, Managing Partner at Activate Venture Partners
Todd Pietri
Activate Venture Partners·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Photo of Dan Becker, Managing Director at Access Biotechnology
Dan Becker
Access Biotechnology·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Mateo (CA), Investors in New York (NY)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in San Francisco Bay Area (Other Lists), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed)
Photo of Joyce Erony, Managing Partner at Amzak Health Investors
Joyce Erony
Amzak Health Investors·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York City
Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in New York City (Other Lists), Investors in Medical Devices (Seed), Investors in BioTech (Series A), Investors in Medical Devices (Series A), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Pre-seed), Investors in BioTech (Pre-seed), Investors in Medical Devices (Pre-seed), Investors in Therapeutics (Series A), Investors in Therapeutics (Seed), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Therapeutics (Series B), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Pre-seed), Investors in Therapeutics (Series A), Investors in BioTech (Pre-seed)
Photo of Zach Lomis, Partner at Palo Santo VC
Zach Lomis
Palo Santo VC·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in New York (NY)
Photo of Shannon Bergstedt, Principal at Foresite Capital
Shannon Bergstedt
Foresite Capital·Principal
Sweet spot: $38.5M
Range: $2.0M - $75.0M
Investors in New York (NY)
Investors in BioTech (Series A), Investors in Pharmaceuticals (Seed), Investors in Pharmaceuticals (Series A), Investors in Pharmaceuticals (Series B), Investors in Therapeutics (Series A), Investors in Therapeutics (Series B), Investors in Drug Delivery (Seed), Investors in Drug Delivery (Series B), Investors in Medical Devices (Seed), Investors in Medical Devices (Series B), Investors in BioTech (Series B), Investors in Medical Devices (Series A), Investors in New York City (Other Lists), Investors in BioTech (Seed), Investors in Health IT (Series A), Investors in Health IT (Seed), Investors in Medical Devices (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Pharmaceuticals (Series B), Investors in Diagnostics (Seed), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Drug Delivery (Series A), Investors in Therapeutics (Seed), Investors in BioTech (Seed), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Diagnostics (Series B), Investors in Diagnostics (Series A), Investors in Diagnostics (Seed), Investors in Therapeutics (Series A), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Drug Delivery (Series A), Investors in Drug Delivery (Series B), Investors in Drug Delivery (Seed), Investors in Digital Health (Series B), Investors in Therapeutics (Seed), Investors in Therapeutics (Series B), Investors in Health IT (Series B), Investors in Health IT (Seed)